Financings in Brief: Perkin-Elmer/Tecan AG
This article was originally published in The Gray Sheet
Executive Summary
Perkin-Elmer/Tecan AG: Integrated life science systems firm Perkin-Elmer plans to acquire 14.5% of Swiss firm Tecan AG under a definitive agreement, giving Perkin-Elmer 52% of the voting rights in Tecan. The firms "contemplate an expanded program to automate molecular biology and pharmaceutical processes designed to accelerate drug discovery, development and testing," Perkin-Elmer states in a release. The agreement with Tecan, "given their expertise in robotics and system automation, enhances our ability to fulfill our vision of providing automated and integrated high-throughput discovery systems that define the molecular medicine paradigm," states Tony White, Perkin-Elmer chairman, president and CEO. Specific terms of the cash deal are not being disclosed...
You may also be interested in...
Health And Wellness Trademark Review 1 December, 2020
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Ipsen CEO Outlines Strategy For Long-Term Success
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
US Startup Ignites Consumer Health Portfolio Build With North American Rights To ThermaCare
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: